Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Net Sales by Business
Proprietary Products$2.62B+12.2%$2.49B+6.8%$2.44B+5.6%$2.4B+3.6%$2.34B-1.5%
Other segment expense (income) by Business
Proprietary Products$21.2M-6.2%$21.1M-4.5%$26.9M+91.8%$26.2M+112%$22.6M+65.3%
Total Assets by Business
Proprietary Products$11.74B$11.43B$11.06B
Operating Income (Loss) by Business
Proprietary Products$715.8M+23.0%$657.2M+13.7%$629.8M+8.8%$612.8M+1.7%$582.1M-12.6%
Selling, general and administrative expenses by Business
Proprietary Products$260.3M+12.6%$255.6M+10.4%$245.5M+5.1%$236.5M-0.3%$231.1M-4.2%
Cost of goods and services sold by Business
Proprietary Products$1.55B+8.2%$1.48B+3.5%$1.47B+4.2%$1.45B+4.8%$1.43B+4.3%
Capital Expenditures by Business
Proprietary Products$188.9M-20.4%$204.3M-17.1%$227.2M-2.1%$227.3M-8.8%$237.3M-7.1%
R&D by Business
Proprietary Products$73.8M+8.8%$74.3M+7.5%$71M+4.9%$69.4M+0.1%$67.8M-1.6%
Depreciation and Amortization by Business
Proprietary Products$143.9M+8.2%$140.2M+7.6%$135M+8.0%$133.7M+11.9%$133M+16.0%
Concentration risk, percentage by Product
Standard Packaging52%-7.0pp55%+7.0pp57%+8.0pp61%+17.0pp59%+14.0pp
Concentration risk, percentage by Geography
Asia Pacific26%25%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How does West Pharmaceutical Services break its business down?
West Pharmaceutical Services (WST) reports net sales by business across 2 parts — Proprietary Products and West Vantage. Each is extracted from the segment footnotes and tracked over time.
Where does West Pharmaceutical Services's segment data come from?
Segment breakdowns are pulled from the segment footnotes in West Pharmaceutical Services's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.